Cart
sales@molnova.com
Quazolast
CAS No. 86048-40-0
Quazolast( —— )
Catalog No. M34121 CAS No. 86048-40-0
Quazolast (RHC 3988) is a potent mediator release inhibitor used as a control against ragweed antigenic nasal challenge and demonstrates superiority over placebo in preventing nasal congestion and nasal itching following such challenges.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 217 | Get Quote |
|
| 5MG | 342 | Get Quote |
|
| 10MG | 504 | Get Quote |
|
| 25MG | 790 | Get Quote |
|
| 50MG | 1086 | Get Quote |
|
| 100MG | 1431 | Get Quote |
|
| 500MG | 2871 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameQuazolast
-
NoteResearch use only, not for human use.
-
Brief DescriptionQuazolast (RHC 3988) is a potent mediator release inhibitor used as a control against ragweed antigenic nasal challenge and demonstrates superiority over placebo in preventing nasal congestion and nasal itching following such challenges.
-
DescriptionQuazolast (RHC 3988) is a potent mediator release inhibitor used as a control against ragweed antigenic nasal challenge and demonstrates superiority over placebo in preventing nasal congestion and nasal itching following such challenges.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number86048-40-0
-
Formula Weight262.65
-
Molecular FormulaC12H7ClN2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(OC)(=O)C=1OC=2C=3C(C(Cl)=CC2N1)=CC=CN3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Nortrachelogenin
Nortrachelogenin ((-)-Wikstromol), which can be extracted from Partrinia scabiosaefolia, has antifungal activity and induces membrane disruption and cysteinyl asparagin-dependent apoptosis.
-
Buddlejasaponin IVb
Buddlejasaponin IVb(200 uM) can shorten thrombin time (TT) by 20.6 %, suggests that it has hemostasis efficacy.
-
Linaprazan glurate
Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate can be used in studies about gastrointestinal inflammatory diseases and peptic ulcer diseases.
